Acorda Therapeutics (ACOR) 30.52 $ACOR
Acorda Therapeutics to Present at the UBS Global Healthcare Conference
Business Wire - Tue May 13, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that Ron Cohen, M.D., Acorda's President and Chief Executive Officer and Michael Rogers, Acorda's Chief Financial Officer, will present at the UBS Global Healthcare Conference on Monday, May 19 at 1:00 p.m. ET at the Sheraton New York Hotel.
Acorda Therapeutics Shares Down 16.4% Since SmarTrend's Sell Call (ACOR)
Comtex SmarTrend(R) - Mon May 12, 10:21AM CDT
SmarTrend identified a Downtrend for Acorda Therapeutics (NASDAQ:ACOR) on April 11th, 2014 at $36.45. In approximately 1 month, Acorda Therapeutics has returned 16.45% as of today's recent price of $30.45.
Traumatic Brain Injury - Pipeline Review, H1 2014: Includes 42 Company and 72 Drug Profiles
M2 - Mon May 12, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vqxgvm/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - ALSP, Inc. - Acorda Therapeutics, Inc. - Adamas Pharmaceuticals, Inc. - Allinky Biopharma - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Bionature E.A. Ltd. - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - D-Pharm Ltd. - Encore Therapeutics Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - Intellect Neurosciences, Inc. - Io Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - M's Science Corporation - MAPREG - MandalMed, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - NeuroHealing Pharmaceuticals Inc. - NeuroNascent, Inc. - NeuroVive Pharmaceutical AB - Omeros Corporation - Oxygen Biotherapeutics, Inc. Drug Profiles: - epoetin alfa - progesterone - progesterone - NeuroSTAT - Oxycyte - VAS-203 - NH-001 - NNZ-2566 - atorvastatin calcium - NeuroSTAT - glyburide - Allopregnanolone - VOLT-02 - SB-623 - RGS-2064 - DP-b99 - amantadine hydrochloride - Drug for Traumatic Brain Injury - MAP-4343 - Posiphen - MultiStem - Lpathomab - RGN-352 - cutamesine - INN-01 - NSI-189 - COG-1410 - AMR-001 - NSI-566 - LB-201 For more information visit http://www.researchandmarkets.com/research/vq...atic_brain
Technical Updates on Biotech Stocks -- Research on Alexion Pharma, Acorda Therapeutics, Clovis Oncology, and Sangamo BioSciences
PR Newswire - Fri May 09, 11:30AM CDT
The markets on Thursday, May 08, 2014 ended on a mixed note as the S&P 500 finished the session 0.14% lower at 1,875.63, and the NASDAQ Composite closed at 4,051.50, down 0.40%. The Dow Jones Industrial Average finished at 16,550.97, up 0.20%. During the session, the five out of ten sectors ended in positive. The session saw a positive impact from Telecommunication Services, Consumer Discretionary and Financials sectors along with a drag from Energy, Utilities and Health Care sectors. The S&P 500 Health Care Sector Index closed the day at 664.48, down 0.53%, while the index has advanced 1.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Acorda Therapeutics Inc. (NASDAQ: ACOR), Clovis Oncology Inc. (NASDAQ: CLVS) and Sangamo BioSciences Inc. (NASDAQ: SGMO). Free technical research on ALXN, ACOR, CLVS and SGMO can be downloaded upon signing up at:
Cerebral Palsy - Pipeline Review, H1 2014: 7 Companies and 11 Drugs Profiled
M2 - Thu May 08, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lpd3rr/cerebral_palsy) has announced the addition of the "Cerebral Palsy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cerebral Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Palsy and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Cerebral Palsy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cerebral Palsy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cerebral Palsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cerebral Palsy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - Allergan, Inc. - Acorda Therapeutics, Inc. - Neuralstem, Inc. - CHA Bio & Diostech Co., Ltd. - RNL BIO Co., Ltd. - Cell Cure Neurosciences, Ltd. - Cellular Biomedicine Group, Inc. Drug Profiles: - onabotulinumtoxinA - dalfampridine ER - epoetin alfa - Umbilical Cord Mesenchymal Stem Cell Transplantation - Cord Blood Stem Cells - Astrostem - Stem Cell Therapy for Central Nervous System Disorders - NSI-566 - NeurArrest - Human Umbilical Cord Derived Mesenchymal Progenitor Cells - Cerebral Palsy Cell Therapy For more information visit http://www.researchandmarkets.com/research/lp...bral_palsy
Acorda Misses on Earnings, Beats Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:43PM CDT
Acorda Therapeutics, Inc.'s (ACOR) first quarter earnings of 2 cents per share missed the Zacks Consensus Estimate of 4 cents.
Epilepsy - Pipeline Review, H1 2014: 43 Companies and 97 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/652dzz/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aestus Therapeutics, Inc. - Allergan, Inc. - Anavex Life Sciences Corp. - Aniona ApS - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - Bio-Link Australia Pty. Ltd. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Celentyx Ltd. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - GW Pharmaceuticals plc - Glialogix, Inc. - Sun Pharmaceutical Industries Limited - UCB S.A. - Upsher-Smith Laboratories, Inc. - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. - XERIS Pharmaceuticals, Inc. - Zalicus Inc. Drug Profiles: - lacosamide - perampanel - eslicarbazepine acetate - diazepam - ADV-5803 - lacosamide - brivaracetam - carbamazepine - carisbamate - diazepam - eslicarbazepine acetate - lacosamide - everolimus - belnacasan - YKP-3089 - naluzotan - DP-VPA - selurampanel - ganaxolone - IPX-218 - topiramate - tonabersat - GWP-42006 - SUN-44 - INS-001 - PF-04895162 - CKD-903 - ANAVEX-2-73 - Antiepileptic Drugs - ANAVEX-19-144 For more information visit http://www.researchandmarkets.com/research/652dzz/epilepsy
Acorda Therapeutics Named One of the Best Places to Work for in New York 2014
Business Wire - Wed May 07, 6:02AM CDT
Biotechnology leader Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of the best companies in New York to work for, based on an independent survey by the Best Companies Group (BCG). The award identifies the best employers in the state, and Acorda was named to the list for the fourth consecutive year.
Acorda Therapeutics Reports First Quarter 2014 Financial Results
Business Wire - Tue May 06, 5:01AM CDT
--Reiterating Full Year 2014 Guidance for AMPYRA Net Revenue of $328-$335 Million
Acorda Down on Plumiaz CRL - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 2:12PM CDT
Shares of Acorda Therapeutics, Inc. (ACOR) were down 9.8% on the news of the issuance of a Complete Response Letter (CRL) by the FDA for the New Drug Application (NDA) for Plumiaz nasal spray.
Downtrend Call Working As Acorda Therapeutics Stock Falls 12.9% (ACOR)
Comtex SmarTrend(R) - Mon May 05, 9:16AM CDT
SmarTrend identified a Downtrend for Acorda Therapeutics (NASDAQ:ACOR) on April 11th, 2014 at $36.45. In approximately 3 weeks, Acorda Therapeutics has returned 12.91% as of today's recent price of $31.74.
Acorda Prescribes bigtincan hub to Field Sales Team to Enhance Content Control and Administration
Business Wire - Mon May 05, 8:00AM CDT
bigtincan, a leader in mobile content enablement, today announced that Acorda Therapeutics has rolled out bigtincan hub to its sales reps. Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological conditions.
Nasdaq stocks posting largest percentage decreases
AP - Fri May 02, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
The Zacks Analyst Blog Highlights: Gilead, Acorda Therapeutics, Hyperion Therapeutics and Medivation
PR Newswire - Fri May 02, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Gilead (Nasdaq:GILD-Free Report), Acorda Therapeutics, Inc. (Nasdaq:ACOR-Free Report), Hyperion Therapeutics, Inc. (Nasdaq:HPTX-Free Report) and Medivation, Inc. (Nasdaq:MDVN-Free Report).
Should You Buy Acorda (ACOR) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 7:48AM CDT
Investors are always looking for stocks that are poised to beat at earnings season and Acorda Therapeutics, Inc. (ACOR) may be one such company
FDA Issues Complete Response Letter for PLUMIAZ(TM), Investigational Medicine for Epilepsy Cluster Seizures
Business Wire - Fri May 02, 5:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PLUMIAZ(TM) (diazepam) Nasal Spray for the treatment of people with epilepsy who experience cluster seizures.
3 Biotech Beats this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu May 01, 11:01AM CDT
Things have been looking up for the biotech industry since last week
Acorda Therapeutics to Present at the Deutsche Bank's 39th Health Care Conference
Business Wire - Wed Apr 30, 6:01AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that Ron Cohen, M.D., Acorda's President and Chief Executive Officer and Michael Rogers, Acorda's Chief Financial Officer, will present at the Deutsche Bank's 39th Annual Health Care Conference on Wednesday, May 7 at 11:30 a.m. ET at the Intercontinental Hotel in Boston.
Global Erectile Dysfunction Therapeutics Pipeline Review 2014 - Analysis of 16 Companies
M2 - Tue Apr 29, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tkfwf9/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Erectile Dysfunction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Erectile Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Sanofi - Suda Ltd - Acorda Therapeutics, Inc. - Chong Kun Dang Pharmaceutical Corp. - IntelGenx Corp. - Apricus Biosciences, Inc. - Palatin Technologies, Inc. - Yuhan Corporation - Futura Medical plc - Fabre-Kramer Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - Aprogen, Inc. - Furiex Pharmaceuticals, Inc. - NanoForm Therapeutics Ltd. - Sagene Pharmaceuticals, Inc. - LondonPharma Ltd For more information visit http://www.researchandmarkets.com/research/tkfwf9/erectile
Acorda Therapeutics to Present at the UBS Global Healthcare Conference
Business Wire - Tue May 13, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that Ron Cohen, M.D., Acorda's President and Chief Executive Officer and Michael Rogers, Acorda's Chief Financial Officer, will present at the UBS Global Healthcare Conference on Monday, May 19 at 1:00 p.m. ET at the Sheraton New York Hotel.
Acorda Therapeutics Shares Down 16.4% Since SmarTrend's Sell Call (ACOR)
Comtex SmarTrend(R) - Mon May 12, 10:21AM CDT
SmarTrend identified a Downtrend for Acorda Therapeutics (NASDAQ:ACOR) on April 11th, 2014 at $36.45. In approximately 1 month, Acorda Therapeutics has returned 16.45% as of today's recent price of $30.45.
Traumatic Brain Injury - Pipeline Review, H1 2014: Includes 42 Company and 72 Drug Profiles
M2 - Mon May 12, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vqxgvm/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - ALSP, Inc. - Acorda Therapeutics, Inc. - Adamas Pharmaceuticals, Inc. - Allinky Biopharma - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Bionature E.A. Ltd. - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - D-Pharm Ltd. - Encore Therapeutics Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - Intellect Neurosciences, Inc. - Io Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - M's Science Corporation - MAPREG - MandalMed, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - NeuroHealing Pharmaceuticals Inc. - NeuroNascent, Inc. - NeuroVive Pharmaceutical AB - Omeros Corporation - Oxygen Biotherapeutics, Inc. Drug Profiles: - epoetin alfa - progesterone - progesterone - NeuroSTAT - Oxycyte - VAS-203 - NH-001 - NNZ-2566 - atorvastatin calcium - NeuroSTAT - glyburide - Allopregnanolone - VOLT-02 - SB-623 - RGS-2064 - DP-b99 - amantadine hydrochloride - Drug for Traumatic Brain Injury - MAP-4343 - Posiphen - MultiStem - Lpathomab - RGN-352 - cutamesine - INN-01 - NSI-189 - COG-1410 - AMR-001 - NSI-566 - LB-201 For more information visit http://www.researchandmarkets.com/research/vq...atic_brain
Technical Updates on Biotech Stocks -- Research on Alexion Pharma, Acorda Therapeutics, Clovis Oncology, and Sangamo BioSciences
PR Newswire - Fri May 09, 11:30AM CDT
The markets on Thursday, May 08, 2014 ended on a mixed note as the S&P 500 finished the session 0.14% lower at 1,875.63, and the NASDAQ Composite closed at 4,051.50, down 0.40%. The Dow Jones Industrial Average finished at 16,550.97, up 0.20%. During the session, the five out of ten sectors ended in positive. The session saw a positive impact from Telecommunication Services, Consumer Discretionary and Financials sectors along with a drag from Energy, Utilities and Health Care sectors. The S&P 500 Health Care Sector Index closed the day at 664.48, down 0.53%, while the index has advanced 1.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Acorda Therapeutics Inc. (NASDAQ: ACOR), Clovis Oncology Inc. (NASDAQ: CLVS) and Sangamo BioSciences Inc. (NASDAQ: SGMO). Free technical research on ALXN, ACOR, CLVS and SGMO can be downloaded upon signing up at:
Cerebral Palsy - Pipeline Review, H1 2014: 7 Companies and 11 Drugs Profiled
M2 - Thu May 08, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lpd3rr/cerebral_palsy) has announced the addition of the "Cerebral Palsy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cerebral Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Palsy and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Cerebral Palsy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cerebral Palsy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cerebral Palsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cerebral Palsy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - Allergan, Inc. - Acorda Therapeutics, Inc. - Neuralstem, Inc. - CHA Bio & Diostech Co., Ltd. - RNL BIO Co., Ltd. - Cell Cure Neurosciences, Ltd. - Cellular Biomedicine Group, Inc. Drug Profiles: - onabotulinumtoxinA - dalfampridine ER - epoetin alfa - Umbilical Cord Mesenchymal Stem Cell Transplantation - Cord Blood Stem Cells - Astrostem - Stem Cell Therapy for Central Nervous System Disorders - NSI-566 - NeurArrest - Human Umbilical Cord Derived Mesenchymal Progenitor Cells - Cerebral Palsy Cell Therapy For more information visit http://www.researchandmarkets.com/research/lp...bral_palsy
Acorda Misses on Earnings, Beats Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:43PM CDT
Acorda Therapeutics, Inc.'s (ACOR) first quarter earnings of 2 cents per share missed the Zacks Consensus Estimate of 4 cents.
Epilepsy - Pipeline Review, H1 2014: 43 Companies and 97 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/652dzz/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aestus Therapeutics, Inc. - Allergan, Inc. - Anavex Life Sciences Corp. - Aniona ApS - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - Bio-Link Australia Pty. Ltd. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Celentyx Ltd. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - GW Pharmaceuticals plc - Glialogix, Inc. - Sun Pharmaceutical Industries Limited - UCB S.A. - Upsher-Smith Laboratories, Inc. - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. - XERIS Pharmaceuticals, Inc. - Zalicus Inc. Drug Profiles: - lacosamide - perampanel - eslicarbazepine acetate - diazepam - ADV-5803 - lacosamide - brivaracetam - carbamazepine - carisbamate - diazepam - eslicarbazepine acetate - lacosamide - everolimus - belnacasan - YKP-3089 - naluzotan - DP-VPA - selurampanel - ganaxolone - IPX-218 - topiramate - tonabersat - GWP-42006 - SUN-44 - INS-001 - PF-04895162 - CKD-903 - ANAVEX-2-73 - Antiepileptic Drugs - ANAVEX-19-144 For more information visit http://www.researchandmarkets.com/research/652dzz/epilepsy
Acorda Therapeutics Named One of the Best Places to Work for in New York 2014
Business Wire - Wed May 07, 6:02AM CDT
Biotechnology leader Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of the best companies in New York to work for, based on an independent survey by the Best Companies Group (BCG). The award identifies the best employers in the state, and Acorda was named to the list for the fourth consecutive year.
Acorda Therapeutics Reports First Quarter 2014 Financial Results
Business Wire - Tue May 06, 5:01AM CDT
--Reiterating Full Year 2014 Guidance for AMPYRA Net Revenue of $328-$335 Million
Acorda Down on Plumiaz CRL - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 2:12PM CDT
Shares of Acorda Therapeutics, Inc. (ACOR) were down 9.8% on the news of the issuance of a Complete Response Letter (CRL) by the FDA for the New Drug Application (NDA) for Plumiaz nasal spray.
Downtrend Call Working As Acorda Therapeutics Stock Falls 12.9% (ACOR)
Comtex SmarTrend(R) - Mon May 05, 9:16AM CDT
SmarTrend identified a Downtrend for Acorda Therapeutics (NASDAQ:ACOR) on April 11th, 2014 at $36.45. In approximately 3 weeks, Acorda Therapeutics has returned 12.91% as of today's recent price of $31.74.
Acorda Prescribes bigtincan hub to Field Sales Team to Enhance Content Control and Administration
Business Wire - Mon May 05, 8:00AM CDT
bigtincan, a leader in mobile content enablement, today announced that Acorda Therapeutics has rolled out bigtincan hub to its sales reps. Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological conditions.
Nasdaq stocks posting largest percentage decreases
AP - Fri May 02, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
The Zacks Analyst Blog Highlights: Gilead, Acorda Therapeutics, Hyperion Therapeutics and Medivation
PR Newswire - Fri May 02, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Gilead (Nasdaq:GILD-Free Report), Acorda Therapeutics, Inc. (Nasdaq:ACOR-Free Report), Hyperion Therapeutics, Inc. (Nasdaq:HPTX-Free Report) and Medivation, Inc. (Nasdaq:MDVN-Free Report).
Should You Buy Acorda (ACOR) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 7:48AM CDT
Investors are always looking for stocks that are poised to beat at earnings season and Acorda Therapeutics, Inc. (ACOR) may be one such company
FDA Issues Complete Response Letter for PLUMIAZ(TM), Investigational Medicine for Epilepsy Cluster Seizures
Business Wire - Fri May 02, 5:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PLUMIAZ(TM) (diazepam) Nasal Spray for the treatment of people with epilepsy who experience cluster seizures.
3 Biotech Beats this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu May 01, 11:01AM CDT
Things have been looking up for the biotech industry since last week
Acorda Therapeutics to Present at the Deutsche Bank's 39th Health Care Conference
Business Wire - Wed Apr 30, 6:01AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that Ron Cohen, M.D., Acorda's President and Chief Executive Officer and Michael Rogers, Acorda's Chief Financial Officer, will present at the Deutsche Bank's 39th Annual Health Care Conference on Wednesday, May 7 at 11:30 a.m. ET at the Intercontinental Hotel in Boston.
Global Erectile Dysfunction Therapeutics Pipeline Review 2014 - Analysis of 16 Companies
M2 - Tue Apr 29, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tkfwf9/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Erectile Dysfunction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Erectile Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Sanofi - Suda Ltd - Acorda Therapeutics, Inc. - Chong Kun Dang Pharmaceutical Corp. - IntelGenx Corp. - Apricus Biosciences, Inc. - Palatin Technologies, Inc. - Yuhan Corporation - Futura Medical plc - Fabre-Kramer Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - Aprogen, Inc. - Furiex Pharmaceuticals, Inc. - NanoForm Therapeutics Ltd. - Sagene Pharmaceuticals, Inc. - LondonPharma Ltd For more information visit http://www.researchandmarkets.com/research/tkfwf9/erectile
